Neovasc Inc. (NVCN)
NVCNPrice: $30.03
Fair Value: 🔒
🔒score
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of... more
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for c... more
Description
Shares
| Market Cap | $82.86M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | CA | CEO | Fredericus A. Colen |
| IPO Date | 2001-05-23 | CAGR | — |
| Employees | 49 | Website | www.neovasc.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NVCN chart loading...
Fundamentals
Technicals
| Enterprise Value | $30.39M | P/E Ratio | -1.99 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 21.78 | P/B Ratio | 5.18 |
| P/CF Ratio | -3.29 | P/FCF Ratio | -3.32 |
| EPS | $-15.07 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 49.37% | Gross Margin | 0.8% |
| Operating Margin | -8.87% | Profit Margin | -10.83% |
| ROE | -1.21% | ROA | -1.06% |
| ROCE | -1.18% | Current Ratio | 2.96 |
| Quick Ratio | 2.85 | Cash Ratio | 2.56 |
| Debt/Equity | 0.82 | Interest Coverage | -22.23 |
| Altman Z Score | -16.74 | Piotroski Score | 3 |